<DOC>
	<DOC>NCT02307682</DOC>
	<brief_summary>The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.This study will be conducted in Argentina, Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Guatemala, Israel, Japan, Mexico, Panama, Peru, New Zealand, and US (including Puerto Rico).</brief_summary>
	<brief_title>Efficacy and Safety of RTH258 Versus Aflibercept</brief_title>
	<detailed_description>This study has 3 arms with a 1:1:1 randomization. Subjects in all arms will have visits every 4 weeks through Week 96. The primary analysis will be performed at Week 48.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provide written informed consent Active CNV lesions secondary to AMD in the study eye Intra and/or subretinal fluid affecting the central subfield of the study eye BCVA between 78 and 23 letters, inclusive, in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) testing Other protocoldefined inclusion criteria may apply Any active intraocular or periocular infection or active intraocular inflammation in either eye Fibrosis or geographic atrophy Any approved or investigational treatment for neovascular AMD (other than vitamin supplements) in the study eye at any time Any history or evidence of a concurrent intraocular condition in the study eye that, in the judgment of the Investigator, could require either medical or surgical intervention during the course of the study to prevent or treat visual loss Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks History or evidence of surgery to the study eye, as specified in the protocol Uncontrolled glaucoma in the study eye Aphakia and/or absence of the posterior capsule in the study eye Use of corticosteroids, ocular and systemic, as specified in the protocol Treatment with aflibercept (EYLEA®), bevacizumab (AVASTIN®), ranibizumab (LUCENTIS®), or pegaptanib (MACUGEN®) in the nonstudy eye, as specified in the protocol History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product History of hypersensitivity to any component of the test article, control article, or ophthalmic dye, as assessed by the Investigator Pregnant, lactating, or women of childbearing potential, unless using effective methods of contraception during dosing of study treatment Stroke or myocardial infarction in the 90 day period prior to enrollment Uncontrolled blood pressure defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg Participation in an investigational drug, biologic, or device study, as specified in the protocol Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AMD</keyword>
	<keyword>CNV</keyword>
	<keyword>IVT</keyword>
</DOC>